NCT07262970 2025-12-04
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
Rezolute
Available
Clinical Trials
11 trialsNCT01916148 2025-04-02
18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
Children's Hospital of Philadelphia
Available
NCT03649438 2024-12-11
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
University of Texas Southwestern Medical Center
No longer available
NCT03015844 2024-07-05
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Northwell Health
Available
NCT01838187 2023-08-18
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Children's Hospital Medical Center, Cincinnati
No longer available
NCT02431715 2023-02-21
18F-FDOPA PET in Neuroendocrine Tumours
British Columbia Cancer Agency
No longer available
NCT02174679 2020-07-27
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Jonsson Comprehensive Cancer Center
No longer available
NCT01377532 2020-05-06
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
University of California, San Francisco
Approved for marketing
NCT01980732 2017-08-23
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Stanford University
No longer available
NCT02375464 2016-11-08
Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Northwell Health
No longer available
NCT02358018 2016-11-02
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
Memorial Sloan Kettering Cancer Center
No longer available